News
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...
Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...
2d
MedPage Today on MSN$5K Birth Reward in Talks; Zepbound Lawsuits; Varenicline for Vape CessationWhite House advisors are mulling over ways to increase the birth rate, including a $5,000 "baby bonus" to mothers. (ABC News) Eli Lilly is suing compounding pharmacies still selling their versions of ...
The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...
In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...
Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and weight-loss drugs.
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results